SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending, fueled by intense community engagement around its multi-chain presence across Cronos, Solana, and Ethereum. Enthusiasts are actively discussing its deflationary burn mechanism and organic growth, positioning it as a potential "king of memes" within the crypto space.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is trending due to community excitement surrounding a rumored collaboration with POL and its recent integration with ACH, signaling a meaningful expansion of its real-world utility. Investors are actively watching Dash, an original privacy coin, to potentially mirror the strong upward movement of Zcash amidst a broader resurgence of interest in the privacy token sector. Many anticipate it is poised for significant gains and breaking key resistance levels.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is actively trending due to its strategic pivot into the high-growth obesity drug market following a recent acquisition and ongoing pipeline developments, including upcoming vaccine trial readouts. The community is keenly focused on the company's ability to execute on these growth drivers and navigate patent expiration pressures, while its strong dividend yield remains a key discussion point for long-term investors.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is a top trending stock, driven by high anticipation for its presentation at the J.P. Morgan Healthcare Conference and the imminent PMDA approval in Japan. The community is buzzing about recent positive clinical data, particularly for pancreatic and skin cancer, which showcases the revolutionary Alpha DaRT technology's potential and is attracting significant institutional interest. This momentum, marked by robust volume and new price levels, underscores investor belief in the company's trajectory within the targeted alpha therapy sector.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is trending strongly as the community buzzes about recent partnerships, notably with World Liberty Financial, and the integration of USD1 for payroll and card services. Investors are enthusiastically discussing ZBCN's robust real-world utility in on-chain payments, low token dilution, and ISO 20022/MiCA compliance, with many anticipating significant growth fueled by its upcoming "Super App" and expanding integrations.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is trending due to surging institutional interest, marked by significant stablecoin inflows and new ETF filings from major financial players. The community is actively discussing large whale accumulations and Solana's growing role as a high-performance blockchain for various applications. Its expanding ecosystem and unique speed position it as a strong contender in the digital asset space, with anticipation for clearer regulatory frameworks.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending amid escalating speculation that Sanofi is preparing an improved takeover offer after an initial bid was rejected. Community discussion points to the company's confidence in its lead drug, AXPAXLI, and an accelerated NDA pathway as key reasons for seeking a higher valuation, with many anticipating a significant premium ahead of upcoming Phase 3 data. This activity highlights broader interest in long-acting therapies for the wet AMD market.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is experiencing intense investor interest following Saudi FDA approval for its ANKTIVA drug in both bladder and lung cancer, complemented by a reported 700% year-over-year revenue surge. The community is eagerly anticipating a significant short squeeze, fueled by enthusiasm for ANKTIVA's chemotherapy-free approach and its potential to revolutionize cancer treatment as a 

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF ($VTI) is trending as it recently achieved new all-time highs, reflecting broad market strength and investor confidence. The community actively discusses VTI as a 'painfully simple yet effective' core holding for diversified, long-term growth, often comparing its steady performance to more concentrated growth funds. This positive sentiment is underpinned by favorable U.S. growth outlooks and an increasing risk appetite across various market sectors.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is trending due to its strategic expansion through acquisitions, recently adding Dynavax and Blueprint Medicines to bolster its vaccine and immunology pipelines. The community is actively discussing a potential sweetened takeover offer for Ocular Therapeutix, alongside ongoing interest in Sanofi's partnership with Novavax. These moves, coupled with the continued strong performance of key drugs like Dupixent, highlight Sanofi's focus on pipeline growth in critical therapeutic areas.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tesla (TSLA) CEO Elon Musk signaled Friday that the company’s long-running ‘Master Plan Part Deux’ may finally be completed next year, nearly a decade after it was first unveiled.&nbsp;Part Deux&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tesla.com/master-plan-part-deux">laid out</a> Tesla’s ambition to create solar roofs with integrated battery storage, expand its EV lineup across major segments, develop self-driving capabilities “10 times safer than that of humans,” and enable cars to generate income for owners when idle.&nbsp;Investors have traditionally tracked Musk’s master plans as roadmaps for Tesla’s future direction.<a href="http://stocktwits.com/symbol/TSLA">Tesla’s stock</a> was down as much as 2.8% in midday trade on Friday. However, retail sentiment on Stocktwits continued to trend in ‘bullish’ territory over the past day.&nbsp;In a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/elonmusk/status/1961450257176502656">post</a> on X, Musk acknowledged that Tesla’s most recent strategy blueprint, the Master Plan Part 3, proved “too complex for almost anyone to understand,” despite its sweeping vision for a global shift to sustainable energy. He promised that Master Plan 4 would be “concise,” hinting at a pared-down approach, rather than the sprawling targets across electric vehicles, energy storage, and autonomous driving&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tesla.com/en_in/master-plan-part-3">described</a> in Master Plan Part 3.&nbsp;<figure class="image"><a href="https://x.com/elonmusk/status/1961450257176502656" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:1080/1771;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_29_21_57_08_14_0b2fce7a16bf2b728d6ffa28c8d60efb_jpg_97856c6a10.webp" alt="Screenshot_2025-08-29-21-57-08-14_0b2fce7a16bf2b728d6ffa28c8d60efb.jpg" width="1080" height="1771"></a><figcaption>Source: @elonmusk/X</figcaption></figure>Musk’s comments come after the CEO had already hinted that he was working on Master Plan 4 during Tesla’s second-quarter 2025 earnings call in July.&nbsp; “What’s going to happen over the next several years is a fundamental transformation of the company from a pre-autonomy world to a post-autonomy [world],” Musk said. “And I’m working on a new Master Plan to articulate that to the Tesla team.” He added that the future will be full of “exciting things” and hinted that the plan will be “profoundly world-changing,” without sharing any additional details.<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.teslarati.com/tesla-ceo-elon-musk-new-master-plan-what-to-expect/">Reports</a> suggest that Master Plan 4 will likely pave the way for a world where self-driving vehicles, such as the Cybercab, and humanoid robots, like Optimus, are in widespread use.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-revokes-intel-samsung-sk-hynix-waivers-on-china-chip-equipment/chtTKpgRdNh">US Revokes Intel, Samsung, SK Hynix Waivers On China Chip Equipment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Tesla CEO Elon Musk attends the official opening of the new Tesla electric car manufacturing plant on March 22, 2022 in Germany. (Photo by Christian Marquardt - Pool/Getty Images)

Musk Says Tesla Will Finish Master Plan Part Deux In 2026, Promises ‘Concise’ Master Plan 4

The company’s Master Plan Part Deux was first unveiled to the public in 2016, and Master Plan Part 3 was unveiled in 2023.

Equity

Amazon, Coinbase and Tesla fall premarket; Apple and Reddit rise

Investing.com -- U.S. stock futures fell Friday in the wake of President Donald Trump extending tariffs on a number of trading partners, while investors digested more earnings from tech giants ahead of a key jobs report.

Tesla sales in France and Denmark continue downward trend

Investing.com -- Tesla Inc (NASDAQ:TSLA) car sales in France and Denmark declined in July for the seventh consecutive month.

Tesla stock: Wolfe sees an improving AI/Autonomy narrative

Investing.com -- Wolfe Research said the investment case for Tesla (NASDAQ:TSLA) is shifting increasingly toward its artificial intelligence and autonomy ambitions, despite a mixed near-term outlook for the core auto business.

Samsung stock receives an upgrade after Tesla contract win

Investing.com -- Samsung Electronics (KS:005930) received an upgrade from Macquarie analysts following confirmation of a major foundry deal with Tesla (NASDAQ:TSLA), a move the broker believes could help turn around the company’s struggling chip manufacturing unit.

Tesla deal could be ’a long-term growth catalyst’ for Samsung’s foundry business

Investing.com -- Samsung Electronics’ newly announced W22.8tn ($16.5bn) foundry contract with Tesla (NASDAQ:TSLA) could be “a long-term growth catalyst” for the company’s chipmaking business, according to Bank of America (BofA) analysts.

Samsung to make Tesla’s AI6 chips under $16.5 billion deal, Musk says

Investing.com -- Tesla (NASDAQ:TSLA) CEO Elon Musk said Monday that the company has signed a $16.5 billion chip supply agreement with Samsung Electronics (KS:005930), a deal that could provide a major boost to the South Korean firm’s unprofitable contract chip manufacturing division.

TSLL
Direxion Daily TSLA Bull 2X Shares

Feed

News

Sentiment

Fundamentals

Info

Latest TSLL News

TSLLDirexion Daily TSLA Bull 2X Shares